triacetyluridine

DRUG3 trials

Sponsors

SWOG Cancer Research Network, Wellstat Therapeutics

Conditions

Drug/Agent Toxicity by Tissue/OrganEsophageal CancerGastric CancerPancreatic CancerSolid Tumors

Phase 1

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

TerminatedNCT00044785

Wellstat TherapeuticsSolid Tumors

Start: 2002-08-31End: 2004-03-31Target: 24Updated: 2005-06-24

Phase 2

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

CompletedNCT00004233

SWOG Cancer Research NetworkEsophageal Cancer, Gastric Cancer

Start: 2001-02-28End: 2007-01-31Updated: 2011-07-25

Phase 3

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

CompletedNCT00024427

Wellstat TherapeuticsDrug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer

Start: 2001-02-28Updated: 2012-06-28